Cite
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
MLA
Candoni, Anna, et al. “Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML Patients Younger than 65 Years.” Leukemia Research, vol. 32, no. 12, Dec. 2008, pp. 1800–08. EBSCOhost, https://doi.org/10.1016/j.leukres.2008.05.011.
APA
Candoni, A., Martinelli, G., Toffoletti, E., Chiarvesio, A., Tiribelli, M., Malagola, M., Piccaluga, P. P., Michelutti, A., Simeone, E., Damiani, D., Russo, D., & Fanin, R. (2008). Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leukemia Research, 32(12), 1800–1808. https://doi.org/10.1016/j.leukres.2008.05.011
Chicago
Candoni, Anna, Giovanni Martinelli, Eleonora Toffoletti, Alexia Chiarvesio, Mario Tiribelli, Michele Malagola, Pier Paolo Piccaluga, et al. 2008. “Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML Patients Younger than 65 Years.” Leukemia Research 32 (12): 1800–1808. doi:10.1016/j.leukres.2008.05.011.